(RTTNews) - The Australian stock market is modestly lower on Tuesday after opening in the green, extending the losses in the previous two sessions, despite the broadly positive cues from Wall Street on Monday. The benchmark S&P/ASX 200 index is falling well below the 8,700.00 lev
(RTTNews) - The Australian stock market is modestly lower on Tuesday after opening in the green, extending the losses in the previous two sessions, despite the broadly positive cues from Wall Street on Monday. The benchmark S&P/ASX 200 index is falling well below the 8,700.00 lev
Golden Cross Alert: 3 Stocks With Major Upside PotentialDarling Ingredients (NYSE:DAR) used its 2026 Investor Day at the New York Stock Exchange to outline a stronger operating outlook, renewed confidence in its renewable diesel joint venture and a capital allocation plan focused
Golden Cross Alert: 3 Stocks With Major Upside PotentialDarling Ingredients (NYSE:DAR) used its 2026 Investor Day at the New York Stock Exchange to outline a stronger operating outlook, renewed confidence in its renewable diesel joint venture and a capital allocation plan focused
designer491/iStock via Getty Images By Benjamin Schroeder , Senior Rates Strategist; Michiel Tukker , Senior UK & Eurozone Rates Strategist; and Padhraic Garvey, CFA , Regional Head of Research, Americas Another wait takes us to the weekend. Another week, and US Treasury stress ramps Given the importance of the US-China bilateral summit this week, the war with Iran is put on the back burner as a f...
designer491/iStock via Getty Images By Benjamin Schroeder , Senior Rates Strategist; Michiel Tukker , Senior UK & Eurozone Rates Strategist; and Padhraic Garvey, CFA , Regional Head of Research, Americas Another wait takes us to the weekend. Another week, and US Treasury stress ramps Given the importance of the US-China bilateral summit this week, the war with Iran is put on the back burner as a front-and-centre issue; at least for President Trump, probably. The messaging is clear – patience, and no agreement given what Iran came back with. In consequence, inflation expectations are re-ratcheting higher, and the US 10yr yield is back above 4.4%. Assuming minimal progress and no lasting agreement for the rest of this week, the odds favour a trek in the direction of 4.5% for the 10yr yield. So far it's been steady and measured, and there, in fact, has been no material selling of Treasuries. Most of the yield movement has been a repricing in line with higher inflation risks. We run the risk of some outright selling, a more disorderly market. We'll see CPI inflation on Tuesday, which will confirm headline inflation for April rounding up to 4% and core inflation rounding up toward 3%. Plus, there is every reason to expect that solidified from the subsequent May readings. With 10yr SOFR in the 4% area, it's only marginally above where headline inflation will print. That tight real interest rate outcome keeps the pressure to the upside for nominal rates. EUR curves still follow the oil price narrative, while UK yields face additional drivers While oil prices rose and dragged rates higher alongside, there were also other narratives putting upward pressure to varying degrees across the different curves. In the eurozone, the bear flattening largely followed the accustomed inflation-driven curve dynamic. Markets nudged up the rate hike discount alongside oil prices to just over 70bp of tightening by year-end. The 10y Bund yield, meanwhile, rose a little further above the 3% ma...
Global central banks’ use of the People’s Bank of China ’s swap lines reached a two‑year high in the first quarter, underscoring rising international demand for the Chinese currency. By the end of March, central banks worldwide had drawn a total of 111.6 billion yuan ($16.4 billion) from the PBOC’s foreign‑exchange swap lines, the highest level since March 2024, according to the Chinese central ba...
Global central banks’ use of the People’s Bank of China ’s swap lines reached a two‑year high in the first quarter, underscoring rising international demand for the Chinese currency. By the end of March, central banks worldwide had drawn a total of 111.6 billion yuan ($16.4 billion) from the PBOC’s foreign‑exchange swap lines, the highest level since March 2024, according to the Chinese central bank’s quarterly report released late Monday. The 17.4 billion yuan increase from the previous three-month period marked the steepest quarter‑on‑quarter rise since 2023, Bloomberg calculations show. The swap line is a key tool for supplying yuan to the global financial system, allowing local institutions to access liquidity through their own central banks to support trade and investment. The latest increase highlights China’s drive for yuan internationalization and countries’ increasing openness to reduce reliance on the dollar. As of the end of 2025, China had signed currency swap lines with 32 countries and regions, totaling 4.52 trillion yuan, according to the central bank’s data.
A tribal nation is likely to succeed in blocking Kalshi from offering sports contracts on its land, a federal judge said in what appears to be the first ruling of its kind against the prediction market operator. The Ho-Chunk Nation, a federally recognized Native American tribe, can move ahead with its lawsuit accusing the company of violating the Indian Gaming Regulatory Act, or IGRA, and has show...
A tribal nation is likely to succeed in blocking Kalshi from offering sports contracts on its land, a federal judge said in what appears to be the first ruling of its kind against the prediction market operator. The Ho-Chunk Nation, a federally recognized Native American tribe, can move ahead with its lawsuit accusing the company of violating the Indian Gaming Regulatory Act, or IGRA, and has shown “a likelihood of success” in its complaint, US District Judge William M. Conley in Madison, Wisconsin, wrote in a ruling Monday. The dispute centers on whether sports-related event contracts are gaming that can be regulated by states’ laws and federal tribal law, or financial instruments that fall under federal oversight. In a fast-moving nationwide legal fight , Kalshi has had mixed results arguing that it should be overseen by the Commodity Futures Trading Commission rather than state officials. Conley’s decision marks a rare victory for a Native American tribe pressing claims against Kalshi under IGRA. A similar showdown is pending at a federal appeals court in California, where several tribes failed to win an injunction they sought in a lower court. Earlier this year, several tribes sought to support Tennessee’s efforts to regulate Kalshi but a judge rejected their request to file a friend-of-the-court brief. The company went on to win a preliminary injunction blocking enforcement by Tennessee officials. In Wisconsin, Conley faulted Kalshi’s interpretation of the tribe’s IGRA-required Tribal-State compact with regulators as “without basis in the text, legislative history or common sense.” Kalshi’s reading of the compact would have only allowed tribal nations and states to sue each other, rather than third parties. Still, Conley denied the Ho-Chunk Nation’s request for a preliminary injunction against Kalshi because the tribe did not show “irreparable harm” if the company continued operating its exchange on a tribal tract of about 17 square miles while the court fight ...
Earnings Call Insights: ZoomInfo Technologies Inc. (GTM) Q1 2026 Management View "We started 2026 by delivering revenue and adjusted operating income above the high end of our Q1 guidance." (CEO Henry Schuck) "As macro conditions worsened at the end of the quarter, we experienced a regression in our downmarket and upmarket growth trajectories." (CEO Schuck) "In the closing days of March and into A...
Earnings Call Insights: ZoomInfo Technologies Inc. (GTM) Q1 2026 Management View "We started 2026 by delivering revenue and adjusted operating income above the high end of our Q1 guidance." (CEO Henry Schuck) "As macro conditions worsened at the end of the quarter, we experienced a regression in our downmarket and upmarket growth trajectories." (CEO Schuck) "In the closing days of March and into April, we saw a trend of AI and agentic confusion in our customer conversations... This led to a pause in purchasing decisions and our software customers were particularly affected." (CEO Schuck) "As a result, we are revising our full year guidance down in conjunction with significant cost reductions that we believe will position us with structurally higher operating margins and create a faster path back to durable growth." (CEO Schuck) "Beginning in Q3, customers will have the flexibility to convert historical per seat spend into consumption across ZoomInfo data, insights, applications and agents." (CEO Schuck) "In Q1, Salesforce released its prospecting agent with ZoomInfo as the first and primary external data provider." (CEO Schuck) "Q1 GAAP revenue was $310 million... adjusted operating income was $110 million... Unlevered free cash flow was $120 million." (CFO Michael O'Brien) "The changes announced today impact 20% of our employees or 600 team members, including closing our facilities in Israel." (CFO O'Brien) Outlook Q2 non-GAAP net income guidance of $0.26 to $0.28 per share vs. $0.27 (analysts estimates); Q2 revenue guidance of $300 million to $303 million vs. $309,767,870 (analysts estimates). "For the full year 2026, we now expect GAAP revenue in the range of $1.185 billion to $1.205 billion" and "adjusted operating income in the range of $437 million to $447 million." (CFO O'Brien) "We plan to roll out a hybrid pricing model later in Q3 that pairs a low annual platform fee with prepurchase credits rather than our traditional seat-based packages." (CFO O'Brien) "...
Earnings Call Insights: Kyntra Bio (KYNB) Q1 2026 Management View CEO Thane Wettig said the quarter’s focus remained on “consistent progress we have made across our portfolio,” highlighting “FG-3246, our potential first-in-class antibody drug conjugate targeting CD46 and its companion PET imaging agent in metastatic castration-resistant prostate cancer” and “roxadustat, our potential treatment for...
Earnings Call Insights: Kyntra Bio (KYNB) Q1 2026 Management View CEO Thane Wettig said the quarter’s focus remained on “consistent progress we have made across our portfolio,” highlighting “FG-3246, our potential first-in-class antibody drug conjugate targeting CD46 and its companion PET imaging agent in metastatic castration-resistant prostate cancer” and “roxadustat, our potential treatment for anemia due to lower-risk myelodysplastic syndromes.” CEO Wettig stated the Phase II monotherapy study for FG-3246 and FG-3180 in the “post-ARPI pre-chemo setting” was “actively enrolling patients at multiple sites in the U.S. with an anticipated interim analysis in the fourth quarter of 2026,” and added, “We now have 21 sites activated in top-tier institutions across the U.S.” CEO Wettig said roxadustat is “advancing as planned,” and added, “We recently received constructive feedback from the FDA on the Phase III design and are in the process of finalizing the protocol,” while reiterating, “we expect to initiate the Phase III trial in the second half of 2026.” CFO David DeLucia said, “For the first quarter of 2026, total revenue was $3.7 million,” and added, “As of March 31, we reported $100.3 million in cash, cash equivalents, investments and accounts receivable” and “expect the company to have cash runway into 2028.” Outlook CEO Wettig reiterated timing catalysts, saying the company expects “interim analysis from the Phase II monotherapy trial in the fourth quarter of 2026” and “initiation of the Phase III trial for roxadustat in lower-risk MDS in the second half of 2026.” CEO Wettig framed the Phase II interim bar as oriented toward continuing to mature rPFS, saying, “we've got a hurdle that is consistent with this composite response of ORR and PSA 50 that we saw in the Phase I monotherapy trial,” and added, “we are most interested in getting to the more fully mature rPFS data in 2027.” Compared with Q4 2025, management’s interim-readout language shifted from “the secon...